Skip to main content

Table 1 Baseline characteristics of adult intensive care unit patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin

From: Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study

Characteristic

Linezolid (n = 101)

Vancomycin (n = 87)

P value

Male, n (%)

63 (62.4)

49 (56.3)

0.457

Hospitalization ≥5 days before therapy for VAP, n (%)

74 (73.3)

50 (57.5)

0.030

Bronchiectasis, n (%)

8 (7.9)

1 (1.1)

0.039

Colonization with MDRO, n (%)

34 (33.7)

32 (36.8)

0.759

Hospitalization ≥2 days in previous 90 days, n (%)

20 (19.8)

17 (19.5)

1.000

Nursing home resident, n (%)

6 (5.9)

5 (5.7)

1.000

Home infusion therapy, n (%)

2 (2.0)

0

0.500

Home wound care, n (%)

5 (5.0)

3 (3.4)

0.727

Active malignancy, n (%)

8 (7.9)

5 (5.7)

0.774

End-stage liver disease, n (%)

9 (8.9)

1 (1.1)

0.022

COPD, n (%)

15 (14.9)

8 (9.2)

0.271

Steroid use, n (%)

4 (4.0)

7 (8.0)

0.351

Risk factors for MDROs, n (%)

88 (87.1)

70 (80.5)

0.236

Cardiac disease, n (%)

29 (28.7)

25 (28.7)

1.000

Renal disease, n (%)

8 (7.9)

6 (6.9)

1.000

Vascular disease, n (%)

20 (19.8)

27 (31.0)

0.092

End-stage renal disease and/or dialysis, n (%)

4 (4.0)

3 (3.4)

1.000

Diabetes, n (%)

29 (28.7)

17 (19.5)

0.174

Respiratory disease, n (%)

24 (23.8)

18 (20.7)

0.726

Multilobar infiltrates, n (%)

39 (38.6)

25 (28.7)

0.168

Severe sepsis, n (%)

78 (77.2)

55 (63.2)

0.038

Appropriate empiric antimicrobial therapy, n (%)

100 (99.0)

85 (97.7)

0.597

Age, median (IQR)

59 (20)

56 (26)

0.246

Body mass index, median (IQR)

28.7 (11.9)

27.7 (9.9)

0.359

CPIS at diagnosis, median (IQR)

6 (3)

6 (2)

0.177

CPIS at day 3, median (IQR)

7 (3)

7 (3)

0.051

APACHE II score, median (IQR)

21 (11)

19 (9)

0.041

Platelet count at diagnosis, median (IQR)

219 (143)

204 (115.5)

0.397

Hemoglobin at diagnosis, median (IQR)

9.5 (1.9)

10 (2.1)

0.026

Creatinine clearance at diagnosis, median (IQR)

78.5 (59.3)

95.9 (69.3)

0.054

Vancomycin MIC (μg/mL, E-test), n (%)

  

0.087

 0.75

1 (2.4)

0

 

 1

5 (11.9)

0

 

 1.5

22 (52.4)

26 (72.2)

 

 2

14 (33.3)

10 (27.8)

 

Vancomycin serum trough level (μg/mL),

   

 mean ± SD

   

 Day 3

13 ± 8

 

 Overall

21 ± 11

 
  1. APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; CPIS, Clinical Pulmonary Infection Score; IQR, interquartile range; MDRO, multidrug-resistant organism; MIC, minimum inhibitory concentration; VAP, ventilator-associated pneumonia.